3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Neoplasms
2
Meningioma
2
Breast Neoplasms
2
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neurofibromatosis 2
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Endometrial Neoplasms
1
Disease
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Advanced Cancer
1
Adenocarcinoma
1
Interventions
Rituximab
259
Cyclophosphamide
238
Etoposide
114
Prednisone
97
Vincristine
96
Doxorubicin
96
Peripheral Blood Stem Cell Transplantation
95
fludarabine phosphate
87
Filgrastim
80
Cytarabine
61
Lenalidomide
60
Mycophenolic Acid
59
Melphalan
59
Radiotherapy
58
Busulfan
52
Cyclosporine
50
Carmustine
49
Whole-Body Irradiation
48
Tacrolimus
46
Methotrexate
42
Antilymphocyte Serum
38
Gemcitabine
33
Ifosfamide
32
Carboplatin
32
fludarabine
31
Dexamethasone
31
polatuzumab vedotin
29
Granulocyte Colony-Stimulating Factor
29
CT-P10
28
Methylprednisolone
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma, Large B-Cell, Diffuse
×
vistusertib
×
Clear all
NCT02752204
2020-11-05
TORCH
University of Birmingham
Phase 2
Completed
36 enrolled